{"id":20899,"date":"2026-10-25T08:38:59","date_gmt":"2026-10-25T03:08:59","guid":{"rendered":"https:\/\/sunpharma.com\/?p=20899"},"modified":"2026-10-25T08:40:51","modified_gmt":"2026-10-25T03:10:51","slug":"at-esmo-2026-sun-pharma-to-present-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-from-one-of-the-largest-prospective-studies-in-advanced-cutaneous-squamous-cell-carcinoma-acscc","status":"publish","type":"post","link":"https:\/\/sunpharma.com\/he\/blog\/at-esmo-2026-sun-pharma-to-present-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-from-one-of-the-largest-prospective-studies-in-advanced-cutaneous-squamous-cell-carcinoma-acscc\/","title":{"rendered":"At ESMO 2026, Sun Pharma to Present Long-Term Follow-up Data on UNLOXCYT\u00ae (cosibelimab-ipdl) from One of the Largest Prospective Studies in Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)"},"content":{"rendered":"<p><a href=\"https:\/\/sunpharma.com\/wp-content\/uploads\/2026\/10\/At-ESMO-2026-Sun-Pharma-to-Present-Long-Term-Follow-up-Data-on-UNLOXCYT\u00ae-cosibelimab-ipdl-from-One-of-the-Larg.pdf\" class=\"read-more-btn\" target=\"_blank\">Read More<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Read More<\/p>","protected":false},"author":4,"featured_media":28,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-20899","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pressreleases"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>At ESMO 2026, Sun Pharma to Present Long-Term Follow-up Data on UNLOXCYT\u00ae (cosibelimab-ipdl) from One of the Largest Prospective Studies in Advanced Cutaneous Squamous Cell Carcinoma (aCSCC) - Sun Pharmaceutical Industries Ltd.<\/title>\n<meta name=\"robots\" content=\"noindex, nofollow\" \/>\n<meta property=\"og:locale\" content=\"he_IL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"At ESMO 2026, Sun Pharma to Present Long-Term Follow-up Data on UNLOXCYT\u00ae (cosibelimab-ipdl) from One of the Largest Prospective Studies in Advanced Cutaneous Squamous Cell Carcinoma (aCSCC) - Sun Pharmaceutical Industries Ltd.\" \/>\n<meta property=\"og:description\" content=\"Read More\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sunpharma.com\/he\/blog\/at-esmo-2026-sun-pharma-to-present-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-from-one-of-the-largest-prospective-studies-in-advanced-cutaneous-squamous-cell-carcinoma-acscc\/\" \/>\n<meta property=\"og:site_name\" content=\"Sun Pharmaceutical Industries Ltd.\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-25T03:08:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-25T03:10:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sunpharma.com\/wp-content\/uploads\/2025\/05\/press_release_caritec.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"626\" \/>\n\t<meta property=\"og:image:height\" content=\"417\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"ananthi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u05e0\u05db\u05ea\u05d1 \u05e2\u05dc \u05d9\u05d3\" \/>\n\t<meta name=\"twitter:data1\" content=\"ananthi\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"At ESMO 2026, Sun Pharma to Present Long-Term Follow-up Data on UNLOXCYT\u00ae (cosibelimab-ipdl) from One of the Largest Prospective Studies in Advanced Cutaneous Squamous Cell Carcinoma (aCSCC) - Sun Pharmaceutical Industries Ltd.","robots":{"index":"noindex","follow":"nofollow"},"og_locale":"he_IL","og_type":"article","og_title":"At ESMO 2026, Sun Pharma to Present Long-Term Follow-up Data on UNLOXCYT\u00ae (cosibelimab-ipdl) from One of the Largest Prospective Studies in Advanced Cutaneous Squamous Cell Carcinoma (aCSCC) - Sun Pharmaceutical Industries Ltd.","og_description":"Read More","og_url":"https:\/\/sunpharma.com\/he\/blog\/at-esmo-2026-sun-pharma-to-present-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-from-one-of-the-largest-prospective-studies-in-advanced-cutaneous-squamous-cell-carcinoma-acscc\/","og_site_name":"Sun Pharmaceutical Industries Ltd.","article_published_time":"2026-10-25T03:08:59+00:00","article_modified_time":"2026-10-25T03:10:51+00:00","og_image":[{"width":626,"height":417,"url":"https:\/\/sunpharma.com\/wp-content\/uploads\/2025\/05\/press_release_caritec.jpg","type":"image\/jpeg"}],"author":"ananthi","twitter_card":"summary_large_image","twitter_misc":{"\u05e0\u05db\u05ea\u05d1 \u05e2\u05dc \u05d9\u05d3":"ananthi"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sunpharma.com\/blog\/at-esmo-2026-sun-pharma-to-present-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-from-one-of-the-largest-prospective-studies-in-advanced-cutaneous-squamous-cell-carcinoma-acscc\/#article","isPartOf":{"@id":"https:\/\/sunpharma.com\/blog\/at-esmo-2026-sun-pharma-to-present-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-from-one-of-the-largest-prospective-studies-in-advanced-cutaneous-squamous-cell-carcinoma-acscc\/"},"author":{"name":"ananthi","@id":"https:\/\/sunpharma.com\/#\/schema\/person\/c7269b4a3d6a22d46bfb1554af8093fa"},"headline":"At ESMO 2026, Sun Pharma to Present Long-Term Follow-up Data on UNLOXCYT\u00ae (cosibelimab-ipdl) from One of the Largest Prospective Studies in Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)","datePublished":"2026-10-25T03:08:59+00:00","dateModified":"2026-10-25T03:10:51+00:00","mainEntityOfPage":{"@id":"https:\/\/sunpharma.com\/blog\/at-esmo-2026-sun-pharma-to-present-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-from-one-of-the-largest-prospective-studies-in-advanced-cutaneous-squamous-cell-carcinoma-acscc\/"},"wordCount":28,"commentCount":0,"image":{"@id":"https:\/\/sunpharma.com\/blog\/at-esmo-2026-sun-pharma-to-present-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-from-one-of-the-largest-prospective-studies-in-advanced-cutaneous-squamous-cell-carcinoma-acscc\/#primaryimage"},"thumbnailUrl":"https:\/\/sunpharma.com\/wp-content\/uploads\/2025\/05\/press_release_caritec.jpg","articleSection":["Press Releases"],"inLanguage":"he-IL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/sunpharma.com\/blog\/at-esmo-2026-sun-pharma-to-present-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-from-one-of-the-largest-prospective-studies-in-advanced-cutaneous-squamous-cell-carcinoma-acscc\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/sunpharma.com\/blog\/at-esmo-2026-sun-pharma-to-present-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-from-one-of-the-largest-prospective-studies-in-advanced-cutaneous-squamous-cell-carcinoma-acscc\/","url":"https:\/\/sunpharma.com\/blog\/at-esmo-2026-sun-pharma-to-present-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-from-one-of-the-largest-prospective-studies-in-advanced-cutaneous-squamous-cell-carcinoma-acscc\/","name":"At ESMO 2026, Sun Pharma to Present Long-Term Follow-up Data on UNLOXCYT\u00ae (cosibelimab-ipdl) from One of the Largest Prospective Studies in Advanced Cutaneous Squamous Cell Carcinoma (aCSCC) - Sun Pharmaceutical Industries Ltd.","isPartOf":{"@id":"https:\/\/sunpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sunpharma.com\/blog\/at-esmo-2026-sun-pharma-to-present-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-from-one-of-the-largest-prospective-studies-in-advanced-cutaneous-squamous-cell-carcinoma-acscc\/#primaryimage"},"image":{"@id":"https:\/\/sunpharma.com\/blog\/at-esmo-2026-sun-pharma-to-present-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-from-one-of-the-largest-prospective-studies-in-advanced-cutaneous-squamous-cell-carcinoma-acscc\/#primaryimage"},"thumbnailUrl":"https:\/\/sunpharma.com\/wp-content\/uploads\/2025\/05\/press_release_caritec.jpg","datePublished":"2026-10-25T03:08:59+00:00","dateModified":"2026-10-25T03:10:51+00:00","author":{"@id":"https:\/\/sunpharma.com\/#\/schema\/person\/c7269b4a3d6a22d46bfb1554af8093fa"},"breadcrumb":{"@id":"https:\/\/sunpharma.com\/blog\/at-esmo-2026-sun-pharma-to-present-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-from-one-of-the-largest-prospective-studies-in-advanced-cutaneous-squamous-cell-carcinoma-acscc\/#breadcrumb"},"inLanguage":"he-IL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sunpharma.com\/blog\/at-esmo-2026-sun-pharma-to-present-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-from-one-of-the-largest-prospective-studies-in-advanced-cutaneous-squamous-cell-carcinoma-acscc\/"]}]},{"@type":"ImageObject","inLanguage":"he-IL","@id":"https:\/\/sunpharma.com\/blog\/at-esmo-2026-sun-pharma-to-present-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-from-one-of-the-largest-prospective-studies-in-advanced-cutaneous-squamous-cell-carcinoma-acscc\/#primaryimage","url":"https:\/\/sunpharma.com\/wp-content\/uploads\/2025\/05\/press_release_caritec.jpg","contentUrl":"https:\/\/sunpharma.com\/wp-content\/uploads\/2025\/05\/press_release_caritec.jpg","width":626,"height":417,"caption":"Sun Pharma introduces a novel class of drug"},{"@type":"BreadcrumbList","@id":"https:\/\/sunpharma.com\/blog\/at-esmo-2026-sun-pharma-to-present-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-from-one-of-the-largest-prospective-studies-in-advanced-cutaneous-squamous-cell-carcinoma-acscc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sunpharma.com\/"},{"@type":"ListItem","position":2,"name":"At ESMO 2026, Sun Pharma to Present Long-Term Follow-up Data on UNLOXCYT\u00ae (cosibelimab-ipdl) from One of the Largest Prospective Studies in Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)"}]},{"@type":"WebSite","@id":"https:\/\/sunpharma.com\/#website","url":"https:\/\/sunpharma.com\/","name":"Sun Pharmaceutical Industries Ltd.","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sunpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"he-IL"},{"@type":"Person","@id":"https:\/\/sunpharma.com\/#\/schema\/person\/c7269b4a3d6a22d46bfb1554af8093fa","name":"ananthi","image":{"@type":"ImageObject","inLanguage":"he-IL","@id":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","caption":"ananthi"},"url":"https:\/\/sunpharma.com\/he\/blog\/author\/ananthi\/"}]}},"_links":{"self":[{"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/posts\/20899","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/comments?post=20899"}],"version-history":[{"count":1,"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/posts\/20899\/revisions"}],"predecessor-version":[{"id":20900,"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/posts\/20899\/revisions\/20900"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/media\/28"}],"wp:attachment":[{"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/media?parent=20899"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/categories?post=20899"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/tags?post=20899"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}